Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Benchmarking Initiative to Reduce Bronchopulmonary Dysplasia (Benchmarking)

3. juni 2015 opdateret af: NICHD Neonatal Research Network

Randomized Controlled Trial of Benchmarking to Reduce Bronchopulmonary Dysplasia to Reduce Bronchopulmonary Dysplasia

This study tested whether Neonatal Intensive Care Unit (NICU) teams trained in benchmarking -- comparing care practices between different NICUs to see which practices prevent bronchopulmonary dysplasia (BPD) -- and quality improvement would change practices and improve rates of survival without BPD in inborn neonates with birth weights of <1250 grams. Benchmarking is a method involving detailed comparisons of processes between similar organizations. For this study, three NRN centers with the lowest rates of BPD have been identified as Benchmark centers. During a 6-month pre-intervention period, details of care practices and management style at these centers were carefully assessed. Based on practices at these Benchmarking sites, we developed a quality improvement program. For this study, 14 other NRN sites were randomized to either implement the benchmarking intervention (intervention sites) or continue with their usual care practices (control sites). After the 1-year intervention period, we compared changes in the rate of survival without BPD at 36 weeks corrected age between the intervention and control sites.

Studieoversigt

Detaljeret beskrivelse

In 1998, 55% of Very Low Birth Weight (VBLW) infants (those born at <1,250g) born at centers in the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network (NRN) either died or developed BPD.

Previous studies within the NICHD Neonatal Research Network showed substantial differences in the incidence of BPD between centers. These differences were not explained by birth weight, gestational age, race, frequency of antenatal steroid use, or incidence of respiratory distress syndrome. Practice differences may contribute to BPD incidence variation. This study evaluated the efficacy of a Benchmarking Initiative to modify clinical care practices and decrease incidence of BPD in VLBW infants.

This study tested whether Neonatal Intensive Care Unit (NICU) teams trained in benchmarking -- comparing care practices between different NICUs to see which practices prevent bronchopulmonary dysplasia (BPD) -- and quality improvement would change practices and improve rates of survival without BPD in inborn neonates with birth weights of <1250 grams. Benchmarking is a method involving detailed comparisons of processes between similar organizations. For this study, three NRN centers with the lowest rates of BPD have been identified as Benchmark centers. During a 6-month pre-intervention period, details of care practices and management style at these centers were carefully assessed. Based on practices at these Benchmarking sites, we developed a quality improvement program. For this study, 14 other NRN sites were randomized to either implement the benchmarking intervention (intervention sites) or continue with their usual care practices (control sites). After the 1-year intervention period, we compared changes in the rate of survival without BPD at 36 weeks corrected age between the intervention and control sites.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

4095

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35233
        • University of Alabama at Birmingham
    • California
      • Palo Alto, California, Forenede Stater, 94304
        • Stanford University
      • San Diego, California, Forenede Stater, 92103-8774
        • University of California at San Diego
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06504
        • Yale University
    • Florida
      • Miami, Florida, Forenede Stater, 33136
        • University of Miami
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30303
        • Emory University
    • Indiana
      • Indianapolis, Indiana, Forenede Stater, 46202
        • Indiana University
    • Michigan
      • Detroit, Michigan, Forenede Stater, 48201
        • Wayne State University
    • New York
      • Rochester, New York, Forenede Stater, 14642
        • University of Rochester
    • North Carolina
      • Charlotte, North Carolina, Forenede Stater, 27157
        • Wake Forest University
      • Durham, North Carolina, Forenede Stater, 27710
        • Duke University
      • Durham, North Carolina, Forenede Stater, 27705
        • RTI International
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45267
        • Cincinnati Children's Medical Center
      • Cleveland, Ohio, Forenede Stater, 44106
        • Case Western Reserve University, Rainbow Babies and Children's Hospital
    • Rhode Island
      • Providence, Rhode Island, Forenede Stater, 02905
        • Brown University, Women & Infants Hospital of Rhode Island
    • Texas
      • Dallas, Texas, Forenede Stater, 75235
        • University of Texas Southwestern Medical Center at Dallas
      • Houston, Texas, Forenede Stater, 77030
        • University of Texas Health Science Center at Houston

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

Ikke ældre end 8 måneder (Barn)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria

  • Infants 501-1,249g birthweight
  • Registered in a participating site

Exclusion Criteria

  • Diagnosed with a syndrome as defined by the Neonatal Research Network's Generic Database Study

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Intervention
Clinical sites randomized to intervention will receive training in the benchmarking BPD management methods identified at the Benchmark sites.

The Benchmarking intervention included:

  1. Data feedback: Using existing data from the NRN Generic Database and Key Care Practices Survey at their NICU to collect data on the perceptions of care.
  2. Training in Continuous Quality Improvement (CQI) Techniques
  3. Review of best existing evidence
  4. Site visits to the Centers with the Lowest Rates of BPD
  5. Selection of Practices to change: Each site team selected practices for modification at their own center
Placebo komparator: Control
Clinical sites randomized to Control will continue with their normal management practices for BPD.
Centers assigned to the control group continued to receive routine information on their own center's outcomes, and all information routinely supplied within the NRN. Control centers did not participate in organized discussions of the interventions applied within the Benchmarking centers. At the completion of the study, Control Centers were offered a workshop on the Benchmarking techniques.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Survival without BPD
Tidsramme: 36 weeks of life
36 weeks of life

Sekundære resultatmål

Resultatmål
Tidsramme
Bronchopulmonary Dysplasia
Tidsramme: 36 weeks of life
36 weeks of life

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Shahnaz Duara, MD, University of Miami
  • Ledende efterforsker: Jon E. Tyson, MD MPH, The University of Texas Health Science Center, Houston
  • Ledende efterforsker: Abbot R. Laptook, MD, University of Texas Southwestern Medical Center
  • Studieleder: Michele C. Walsh, MD, Case Western Reserve University, Rainbow Babies & Children's Hospital

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. marts 2001

Primær færdiggørelse (Faktiske)

1. maj 2004

Studieafslutning (Faktiske)

1. maj 2004

Datoer for studieregistrering

Først indsendt

25. august 2003

Først indsendt, der opfyldte QC-kriterier

25. august 2003

Først opslået (Skøn)

26. august 2003

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

8. juni 2015

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. juni 2015

Sidst verificeret

1. juni 2015

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • NICHD-NRN-0025
  • U10HD021364 (U.S. NIH-bevilling/kontrakt)
  • U10HD021373 (U.S. NIH-bevilling/kontrakt)
  • U10HD021385 (U.S. NIH-bevilling/kontrakt)
  • U10HD027851 (U.S. NIH-bevilling/kontrakt)
  • U10HD027853 (U.S. NIH-bevilling/kontrakt)
  • U10HD027856 (U.S. NIH-bevilling/kontrakt)
  • U10HD027871 (U.S. NIH-bevilling/kontrakt)
  • U10HD027880 (U.S. NIH-bevilling/kontrakt)
  • U10HD027904 (U.S. NIH-bevilling/kontrakt)
  • U10HD034216 (U.S. NIH-bevilling/kontrakt)
  • U10HD021415 (U.S. NIH-bevilling/kontrakt)
  • U10HD027881 (U.S. NIH-bevilling/kontrakt)
  • M01RR008084 (U.S. NIH-bevilling/kontrakt)
  • M01RR006022 (U.S. NIH-bevilling/kontrakt)
  • M01RR000750 (U.S. NIH-bevilling/kontrakt)
  • M01RR000070 (U.S. NIH-bevilling/kontrakt)
  • M01RR000997 (U.S. NIH-bevilling/kontrakt)
  • U10HD021397 (U.S. NIH-bevilling/kontrakt)
  • U10HD034167 (U.S. NIH-bevilling/kontrakt)
  • M01RR001032 (U.S. NIH-bevilling/kontrakt)
  • M01RR002172 (U.S. NIH-bevilling/kontrakt)
  • M01RR002635 (U.S. NIH-bevilling/kontrakt)
  • U01HD036790 (U.S. NIH-bevilling/kontrakt)

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner